Chinese drug regulators approved the everolimus tablets produced by Zhejiang Hisun Pharmaceutical (SHA:600267), according to a Wednesday disclosure to the Shanghai bourse.
The drug approval is valid through Jan. 1, 2030.
Everolimus is indicated for patients with kidney cancer whose prior treatments have failed.
The drug is also indicated for patients with advanced pancreatic neuroendocrine tumors, and advanced non-functional gastrointestinal or pulmonary neuroendocrine tumors, among others, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments